AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23280604 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 94
Study 23280604 — intervention group
Group type: COMPARATOR
Intervention: General recreational activities
Number of subjects: 94
Study 21752247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 34
Study 21752247 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 34
Study 19857076 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of jelly containing 0.3 g of S. euboea extract
Number of subjects: 51
Study 19857076 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (daily consumption of the same jelly without the enrichment)
Number of subjects: 51
Study 17156591 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour pamidronate infusion
Number of subjects: 169
Study 17156591 — intervention group
Group type: COMPARATOR
Intervention: 2-hour pamidronate infusion
Number of subjects: 169
Study 17156591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple myeloma subgroup
Number of subjects: 169
Study 17156591 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic breast cancer subgroup
Number of subjects: 169
Study 15054030 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched randomizations using the signed rank test
Number of subjects: 132
Study 15054030 — intervention group
Group type: COMPARATOR
Intervention: Unmatched randomizations using the rank sum test
Number of subjects: 132
Study 15054030 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched randomizations
Number of subjects: 132
Study 11694775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 24-hour infusion of 5-fluorouracil (5-FU) 2,600 mg/m2 with folinic acid (FA) 500 mg/m2
Number of subjects: 28
Study 11694775 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus 5-FU/FA with local radiation
Number of subjects: 28
Study 9366934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (8.5 +/- 1.5 ml)
Number of subjects: 24
Study 9366934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8.3 +/- 1.8 ml)
Number of subjects: 24
Study 8181207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg
Number of subjects: 178
Study 8181207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 178
Study 8181207 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg
Number of subjects: 178
Study 3111360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg per dose administered intravenously every 8 h for 14 days
Number of subjects: 85
Study 3111360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 75 mg/kg per dose administered intravenously every 8 h for 14 days
Number of subjects: 85
Study 3111360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (various dosages)
Number of subjects: 85
Study 3111360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 85
Study 29168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole for 4 months
Number of subjects: 119
Study 29168427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole
Number of subjects: 119
Study 27733020 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxygen therapy
Number of subjects: 20
Study 27733020 — intervention group
Group type: COMPARATOR
Intervention: Standard care (regular dressings)
Number of subjects: 20
Study 24729102 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of alpha lipoic acid (ALA) supplementation daily for 8 weeks
Number of subjects: 60
Study 24729102 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules daily for 8 weeks
Number of subjects: 60
Study 21106264 — intervention group
Group type: EXPERIMENTAL
Intervention: IV N-acetylcysteine plus high-dose hydration with normal saline
Number of subjects: 220
Study 21106264 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hydration with normal saline
Number of subjects: 220
Study 21106264 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration with normal saline
Number of subjects: 220
Study 20369525 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft (group A)
Number of subjects: 69
Study 20369525 — intervention group
Group type: COMPARATOR
Intervention: Gamma irradiated allograft (group B)
Number of subjects: 69
Study 18680998 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia scheme using ketamin
Number of subjects: 0
Study 18680998 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intensive therapy schemes
Number of subjects: 0
Study 15768050 — intervention group
Group type: COMPARATOR
Intervention: APC expression levels in leukocytes of relapse patients taking antipsychotic medication
Number of subjects: 89
Study 15768050 — intervention group
Group type: COMPARATOR
Intervention: APC expression levels in leukocytes of first-episode drug-naïve patients
Number of subjects: 89
Study 15768050 — intervention group
Group type: EXPERIMENTAL
Intervention: APC expression levels in leukocytes of healthy controls
Number of subjects: 89
Study 15768050 — intervention group
Group type: COMPARATOR
Intervention: Three SNPs (rs2229992, rs42427, rs465899) at the exon region of APC
Number of subjects: 89
Study 15768050 — intervention group
Group type: COMPARATOR
Intervention: APC haplotypes from rs2229992-rs42427-rs465899
Number of subjects: 89
Study 15768050 — intervention group
Group type: COMPARATOR
Intervention: C-A-T haplotype frequency
Number of subjects: 89
Study 12465429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + MMF + Steroids (Tac/MMF/S)
Number of subjects: 489
Study 12465429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Azathioprine + Steroids (Tac/Aza/S)
Number of subjects: 489
Study 12465429 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + MMF (Tac/MMF)
Number of subjects: 489
Study 12465429 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + Azathioprine (Tac/Aza)
Number of subjects: 489
Study 10502909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (1 mg.kg‐1.hr‐1)
Number of subjects: 60
Study 10502909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 60
Study 10502909 — intervention group
Group type: COMPARATOR
Intervention: No postoperative sedation
Number of subjects: 60
Study 8746887 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 0
Study 8746887 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 0
Study 8746887 — intervention group
Group type: COMPARATOR
Intervention: Difference in median survival times between treatment groups
Number of subjects: 0
Study 1646250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human calcitonin (hCT) plus sodium glycocholate (SGC)
Number of subjects: 27
Study 1646250 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular human calcitonin (hCT) 100 U on alternate days
Number of subjects: 27
Study 1646250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human calcitonin (hCT) 100 U/day
Number of subjects: 27
Study 1646250 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular human calcitonin (hCT) 100 U/day
Number of subjects: 27
Study 878552 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr‐Edwards (SEM) prostheses
Number of subjects: 50
Study 878552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lillehei‐Kaster (LKM) prostheses
Number of subjects: 50
Study 878552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bjork‐Shiley (BSM) prostheses
Number of subjects: 50
Study 30633057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Number of subjects: 90
Study 30633057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Number of subjects: 90
Study 30633057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed flow oxygen (1 to 5 L/min for patients)
Number of subjects: 90
Study 30633057 — intervention group
Group type: COMPARATOR
Intervention: ETCO2 measurements without administering oxygen
Number of subjects: 90
Study 30272234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2 with/without cyclic vaginal progesterone
Number of subjects: 596
Study 27397522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (50 mg every other day)
Number of subjects: 72
Study 27397522 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (10 mg per day)
Number of subjects: 72
Study 27397522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 72
Study 27397522 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 72
Study 26431666 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine combined with doxycycline
Number of subjects: 60
Study 26431666 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (control)
Number of subjects: 60
Study 23537882 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (12-week, twice-weekly)
Number of subjects: 156
Study 23537882 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 156
Study 21806298 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral intervention
Number of subjects: 61
Study 21806298 — intervention group
Group type: COMPARATOR
Intervention: Usual home visiting services (Control)
Number of subjects: 61
Study 19780539 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose milk protein (BSMP)
Number of subjects: 6
Study 19780539 — intervention group
Group type: EXPERIMENTAL
Intervention: non-nutritive sweetener milk protein (BNMP)
Number of subjects: 6
Study 19780539 — intervention group
Group type: COMPARATOR
Intervention: high milk protein (CMP)
Number of subjects: 6
Study 19780539 — intervention group
Group type: COMPARATOR
Intervention: reference dark chocolate (CDK)
Number of subjects: 6
Study 16113035 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block (TB) functional appliance
Number of subjects: 38
Study 16113035 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 38
Study 15308927 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 15308927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11822612 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medical acupuncture treatment using an average of 12-13 needles per treatment, with more than 85 different acupoints utilized.
Number of subjects: 150
Study 11822612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatments including heat (36%-67%) and cupping (16%-21%).
Number of subjects: 150
Study 9809707 — intervention group
Group type: EXPERIMENTAL
Intervention: tirilazad mesylate
Number of subjects: 0
Study 7877115 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullary system activation measured by norepinephrine (NE) and normetanephrine excretion
Number of subjects: 0
Study 7877115 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar depression
Number of subjects: 0
Study 7877115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar depression
Number of subjects: 0
Study 3278694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 0
Study 3278694 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 0
Study 31696972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity cognitive behavioural therapy (LICBT)
Number of subjects: 253
Study 31696972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment variables (unemployment, suicide risk, neglect, medication, previous or concurrent treatments, longer duration of difficulties, comorbidities)
Number of subjects: 253
Study 29380013 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg Q6M for 10 years
Number of subjects: 12
Study 29380013 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg Q6M for 7 years
Number of subjects: 12
Study 28664242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 once weekly for 4 weeks)
Number of subjects: 51
Study 28664242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 51
Study 24902673 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (64 patients, 12 sessions of 90 min/week for 3 months)
Number of subjects: 127
Study 24902673 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (63 patients, 12 sessions of 60 min/week for 3 months)
Number of subjects: 127
Study 23435876 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-D3 (calcitriol) at 60 mcg/m2 every 21 days with cisplatin 75 mg/m2 and docetaxel 75 mg/m2
Number of subjects: 34
Study 23435876 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP rs3787554 (C > T)
Number of subjects: 34
Study 23435876 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP rs2762939 (C > G)
Number of subjects: 34
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered females
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered males
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpartnered females
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: White females
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐white males
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered whites
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpartnered males
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: White males
Number of subjects: 1736
Study 21549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpartnered whites
Number of subjects: 1736
Study 18458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg nightly for 8 weeks) + Escitalopram (10 mg for 10 weeks)
Number of subjects: 595
Study 18458207 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone + Escitalopram
Number of subjects: 595
Study 18458207 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Escitalopram
Number of subjects: 595
Study 16453155 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT
Number of subjects: 28
Study 16453155 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 28
Study 14990264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyl-glutamine-supplemented parenteral nutrition (20 g of glutamine)
Number of subjects: 54
Study 14990264 — intervention group
Group type: COMPARATOR
Intervention: Standard glutamine-free parenteral nutrition
Number of subjects: 54
Study 14990264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyl-glutamine-supplemented parenteral nutrition
Number of subjects: 54
Study 11380464 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3 plus high‐dose cytarabine (HIDAC‐3‐7) chemotherapy
Number of subjects: 470
Study 11380464 — intervention group
Group type: COMPARATOR
Intervention: 7‐3 chemotherapy (standard dose cytarabine and daunorubicin)
Number of subjects: 470
Study 11380464 — intervention group
Group type: COMPARATOR
Intervention: 7‐3 plus etoposide (7‐3‐7) chemotherapy
Number of subjects: 470
Study 11380464 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation in first CR
Number of subjects: 470
Study 9052890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (calcium channel blocker)
Number of subjects: 34
Study 9052890 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 34
Study 7639352 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52021 (120 mg)
Number of subjects: 28
Study 7639352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3351343 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 French catheters (group I)
Number of subjects: 200
Study 3351343 — intervention group
Group type: COMPARATOR
Intervention: 8 French catheters (group II)
Number of subjects: 200
Study 31451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 217
Study 31451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (4 mg/kg)
Number of subjects: 217
Study 31451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (50 mg/kg)
Number of subjects: 217
Study 27568351 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight Sodium Hyaluronate (3%) plus saline solution (3 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Number of subjects: 48
Study 27568351 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (6 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Number of subjects: 48
Study 27568351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days, and 12.5 mg for 4 days).
Number of subjects: 48
Study 26258474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment with artemether-lumefantrine (ISTp-AL)
Number of subjects: 5354
Study 26258474 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Preventive Treatment with sulfadoxine-pyrimethamine (IPTp-SP)
Number of subjects: 5354
Study 23010608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted prospective memory intervention delivered by nurses in the home.
Number of subjects: 0
Study 23010608 — intervention group
Group type: COMPARATOR
Intervention: Education control group.
Number of subjects: 0
Study 23010608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted prospective memory intervention.
Number of subjects: 0
Study 21781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 182 mg/day for fast acetylators
Number of subjects: 85
Study 21781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 83 mg/day for slow acetylators
Number of subjects: 85
Study 21781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 182 mg/day for cancer patients (fast acetylators)
Number of subjects: 85
Study 21781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 83 mg/day for cancer patients (slow acetylators)
Number of subjects: 85
Study 21781652 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine for healthy volunteers (fast acetylators)
Number of subjects: 85
Study 21781652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine for healthy volunteers (slow acetylators)
Number of subjects: 85
Study 19349894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine supplementation (36.2 g of l-arginine-HCl)
Number of subjects: 18
Study 19349894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (51.2 g alanine)
Number of subjects: 18
Study 17968821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 654
Study 17968821 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 654
Study 17968821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Glycerol
Number of subjects: 654
Study 17968821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 15961217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX) 50 nM dissolved in 10% ethanol in saline
Number of subjects: 28
Study 15961217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle solution)
Number of subjects: 28
Study 15961217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX)
Number of subjects: 28
Study 12009347 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) for 6 months
Number of subjects: 10
Study 9538966 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro administered 10 min preprandial
Number of subjects: 20
Study 9538966 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro administered 20 min postprandial
Number of subjects: 20
Study 9538966 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro administered preprandially with high-carbohydrate meals
Number of subjects: 20
Study 9538966 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro administered preprandially with solid high-fat meal
Number of subjects: 20
Study 7480971 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine administered intravenously before and during anesthesia
Number of subjects: 60
Study 7480971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taurine)
Number of subjects: 60
Study 2964388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil (5-FU) or 5-fluorouracil-deoxyribose as single agents or in combination with other drugs
Number of subjects: 9
Study 30106534 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluding toothpaste (8% strontium acetate, 1,040 ppm fluoride)
Number of subjects: 20
Study 30106534 — intervention group
Group type: COMPARATOR
Intervention: Non-occluding toothpaste (1,450 ppm fluoride)
Number of subjects: 20
Study 29200982 — intervention group
Group type: EXPERIMENTAL
Intervention: Native whey protein (2×20 g)
Number of subjects: 24
Study 29200982 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC‐80 (2×20 g)
Number of subjects: 24
Study 26286331 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-development coaching programme (two-day workshop)
Number of subjects: 317
Study 26286331 — intervention group
Group type: COMPARATOR
Intervention: Active placebo programme (five-hour workshop)
Number of subjects: 317
Study 26286331 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-development coaching programme
Number of subjects: 317
Study 26286331 — intervention group
Group type: COMPARATOR
Intervention: Active placebo programme
Number of subjects: 317
Study 23059756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of chondroitin 4&6 sulfate 1200 mg (CS 1200)
Number of subjects: 353
Study 23059756 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400)
Number of subjects: 353
Study 23059756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353